1Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibiter therapy in patients with heart failure or left ventricular dysfunction : A systemic overview of data from individual patients. ACE-Inhibiter Myocardial Infarction Collaborative Group[J]. Lancet ,2000 ;355 : 1575-81.
2Johnson D ,Jin Y, Quan H, et al. Beta-blockers and angiotensin-converting enzyme inhibiters/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta Canada [J]. J Am Coll Cardiol,2003 ;42 : 1438-45.
3Masoudi FA, Rathore SS, Wang Y, et al. National patterns of use and effectiveness of angiotensiu-eonverting enzyme inhibiters in older patients with heart failure and left ventrieular systolic dysfunction [J]. Circulation ,2004 ; 110:724-31.
4Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990-2002[J]. J Am Coll Cardiol,2003 :41:56-61.
5Foody JM, Rathore SS, Wang Y, et al. Predictors of cardiologist care for older patients hospitalized for heart failure [J]. Am Heart J, 2004 ; 147 : 66-73.
6Chen YT, Wang Y, Radford M J, et al. Angiotensin-converting enzyme inhibiter dosages in elderly patients with heart failure [J]. Am Heart J, 2001 ;141:410-7.
7Rochon PA, Sykora K, Bronskill SE, et al. Use of angiotensin-converting enzyme inhibiter therapy and dose-related outcomes in older adults with new heart failure in the eommunity[J]. J Gen Intern Med ,2004, 19:676- 83.
8Manyemba J, Mangoni AA, Pettingale KW, et al. Determinants of failure to prescribe target doses of angiotensin-converting enzyme inhibiters for heart failure[J]. Eur J Heart Fail,2003 ;5:693-6.
9Lien CT, Gillespie ND, Struthers AD, et al. Heart failure in frail elderly patients : Diagnostic difficulties, co-morbidities, poly-pharmacy and treatment dilemmas[J]. Eur J Heart Fail ,2002 ;4:91-8.
10Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting [J]. JAMA ,2003 ;289 : 1107-16.
7Meurin P.The ASCOT triaL, clarifying the role of ACE inhibition in the reduction of carliovascular events in patients with hypertension[J].Am J Cardioyasc Drugs, 2006, 6(5): 327-334.
8Johnson JA.Pharmacogenomics of antihypertensive drug past, present and future[J]. Pharmacogenomics, 2010, 11 (4) .. 487-491.
9Or.ova EM, Kiiakbaev GK, Kobalava ZhD. Inflammation and choronic heart failure. The role of statins [J]. Kadiogiia, 2007, 47 (1) : 52 -64. im i rga.
10Munk PS, Larsen AI. Inflammation and C -reactive protein in eardio- vaseulardisease [J]. Tidsskr Nor Laegeforen, 2009, 129 (12): 1221 - 1224.
